Trial · NCT01251978
Ranibizumab as Adjuvant Therapy for the Treatment of Choroidal Melanoma (Cohort 2)
NCT01251978, Phase 2, Completed, New England Retina Associates; results first posted 2016-10-19
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Ranibizumab as Adjuvant Therapy for the Treatment of Choroidal Melanoma (Cohort 2). Trials, record NCT01251978. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01251978
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Ranibizumab as Adjuvant Therapy for the Treatment of Choroidal Melanoma (Cohort 2)
- NCT number
- NCT01251978
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 10 participants, actual
- Lead sponsor
- New England Retina Associates
- Conditions
- Choroidal Melanoma
- Interventions
- Ranibizumab 2 mg, 0.5 mg Ranibizumab
- First posted
- 2010-12-02
- Last updated
- 2016-10-19
- Results first posted
- 2016-10-19
Source ClinicalTrials.gov
Registered outcomes3
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | To Evaluate the Safety/Efficacy of Intravitreal Injection of High Dose Ranibizumab Combined With TTT + ICG-based Photodynamic Therapy in the Treatment of Choroidal Melanoma by Reporting the Number of Participants With Complications. | 1 year | |
| Secondary | Tumor Thickness | baseline and 1 year | |
| Secondary | Visual Acuity (LogMar) | 12 months |
Source ClinicalTrials.gov
Outcomes3
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | To Evaluate the Safety/Efficacy of Intravitreal Injection of High Dose Ranibizumab Combined With TTT + ICG-based Photodynamic Therapy in the Treatment of Choroidal Melanoma by Reporting the Number of Participants With Complications. | 1 year | complications were only assessed in the high dose group | participant | NUMBER |
| SECONDARY | Tumor Thickness | baseline and 1 year | millimeters (mm) | MEAN | |
| SECONDARY | Visual Acuity (LogMar) | 12 months | LogMar | NUMBER |
Source ClinicalTrials.gov
Results by group25
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
To Evaluate the Safety/Efficacy of Intravitreal Injection of High Dose Ranibizumab Combined With TTT + ICG-based Photodynamic Therapy in the Treatment of Choroidal Melanoma by Reporting the Number of Participants With Complications. | High Dose Ranibizumab | vascular occlusion | 4 | participant | |
To Evaluate the Safety/Efficacy of Intravitreal Injection of High Dose Ranibizumab Combined With TTT + ICG-based Photodynamic Therapy in the Treatment of Choroidal Melanoma by Reporting the Number of Participants With Complications. | High Dose Ranibizumab | retinal detachment | 1 | participant | |
To Evaluate the Safety/Efficacy of Intravitreal Injection of High Dose Ranibizumab Combined With TTT + ICG-based Photodynamic Therapy in the Treatment of Choroidal Melanoma by Reporting the Number of Participants With Complications. | High Dose Ranibizumab | persistent sub retinal fluid (srf) | 1 | participant | |
To Evaluate the Safety/Efficacy of Intravitreal Injection of High Dose Ranibizumab Combined With TTT + ICG-based Photodynamic Therapy in the Treatment of Choroidal Melanoma by Reporting the Number of Participants With Complications. | High Dose Ranibizumab | CME | 1 | participant | |
To Evaluate the Safety/Efficacy of Intravitreal Injection of High Dose Ranibizumab Combined With TTT + ICG-based Photodynamic Therapy in the Treatment of Choroidal Melanoma by Reporting the Number of Participants With Complications. | High Dose Ranibizumab | metastatic death | 1 | participant | |
| Tumor Thickness | High Dose Ranibizumab | baseline | 4.85 | Full Range 2.5 to 7.48 | millimeters (mm) |
| Tumor Thickness | Standard Dose Ranibizumab | baseline | 2.91 | Full Range 2.5 to 3.5 | millimeters (mm) |
| Tumor Thickness | High Dose Ranibizumab | 12 month | 2.68 | Full Range NA to NA | millimeters (mm) |
| Tumor Thickness | Standard Dose Ranibizumab | 12 month | 0.79 | Full Range NA to NA | millimeters (mm) |
| Visual Acuity (LogMar) | High Dose Ranibizumab | Patient 01 | NA | LogMar |
1 to 10 of 25Source ClinicalTrials.gov
See all 25 results by groupParticipant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | High Dose Ranibizumab | 5 | |
| Overall Study | STARTED | Standard Dose Ranibizumab | 3 | |
| Overall Study | COMPLETED | High Dose Ranibizumab | 5 | |
| Overall Study | COMPLETED | Standard Dose Ranibizumab | 3 | |
| Overall Study | NOT COMPLETED | High Dose Ranibizumab | 0 | |
| Overall Study | NOT COMPLETED | Standard Dose Ranibizumab | 0 |
Source ClinicalTrials.gov
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | High Dose Ranibizumab | ||
| Total, all-cause mortality | Standard Dose Ranibizumab | ||
| Total, other adverse events | High Dose Ranibizumab | 0 | 0 |
| Total, other adverse events | Standard Dose Ranibizumab | 0 | 0 |
| Total, serious adverse events | High Dose Ranibizumab | 0 | 0 |
| Total, serious adverse events | Standard Dose Ranibizumab | 0 | 0 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT01251978
GET https://conductscience.org/api/trials/v1/NCT01251978/results?page=2